Do analysts prefer GMTX or KRYS?

Krystal Biotech has a consensus price target of $365.80, suggesting a potential upside of 7.04%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Krystal Biotech is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Krystal Biotech 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.92

Do analysts prefer GMTX or ARWR?

Arrowhead Pharmaceuticals has a consensus price target of $99.15, indicating a potential upside of 48.08%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Arrowhead Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.64

Do analysts prefer KYMR or GMTX?

Kymera Therapeutics currently has a consensus price target of $133.21, suggesting a potential upside of 15.36%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kymera Therapeutics is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kymera Therapeutics 1 Sell rating(s) 2 Hold rating(s) 22 Buy rating(s) 1 Strong Buy rating(s) 2.88 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer ABVX or GMTX?

Abivax currently has a consensus target price of $156.69, suggesting a potential upside of 66.46%. Given Abivax's stronger consensus rating and higher probable upside, equities analysts clearly believe Abivax is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abivax 1 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.88 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, ABVX or GMTX?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A

Is ABVX or GMTX more profitable?

Gemini Therapeutics' return on equity of -38.78% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -91.69% -71.96% Gemini Therapeutics N/A -38.78% -35.88%

Do analysts rate GMTX or PTGX?

Protagonist Therapeutics has a consensus price target of $147.13, suggesting a potential upside of 6.08%. Given Protagonist Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protagonist Therapeutics is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Protagonist Therapeutics 0 Sell rating(s) 2 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 2.89

Gemini Therapeutics (GMTX) Competitors

$68.48 -0.01 (-0.01%)

As of 09/22/2026

Compare

GMTX vs. KRYS, ARWR, KYMR, ABVX, and PTGX

Should you buy Gemini Therapeutics stock or one of its competitors? Gemini Therapeutics's main competitors and comparable companies include Krystal Biotech (KRYS), Arrowhead Pharmaceuticals (ARWR), Kymera Therapeutics (KYMR), Abivax (ABVX), and Protagonist Therapeutics (PTGX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Gemini Therapeutics compare to Krystal Biotech?

Gemini Therapeutics (NASDAQ:GMTX) and Krystal Biotech (NASDAQ:KRYS) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Krystal Biotech has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Krystal Biotech	$389.13M	26.00	$204.83M	$7.98	42.83

Krystal Biotech has a consensus price target of $365.80, suggesting a potential upside of 7.04%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Krystal Biotech is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Gemini Therapeutics has a beta of -0.12, suggesting that its stock price is 112% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Krystal Biotech had 7 more articles in the media than Gemini Therapeutics. MarketBeat recorded 7 mentions for Krystal Biotech and 0 mentions for Gemini Therapeutics. Krystal Biotech's average media sentiment score of 1.22 beat Gemini Therapeutics' score of 0.00 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Krystal Biotech	Positive

Krystal Biotech has a net margin of 54.82% compared to Gemini Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 19.34% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Krystal Biotech	54.82%	19.34%	17.65%

Summary

Krystal Biotech beats Gemini Therapeutics on 16 of the 16 factors compared between the two stocks.

How does Gemini Therapeutics compare to Arrowhead Pharmaceuticals?

Gemini Therapeutics (NASDAQ:GMTX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

In the previous week, Arrowhead Pharmaceuticals had 4 more articles in the media than Gemini Therapeutics. MarketBeat recorded 4 mentions for Arrowhead Pharmaceuticals and 0 mentions for Gemini Therapeutics. Arrowhead Pharmaceuticals' average media sentiment score of 0.15 beat Gemini Therapeutics' score of 0.00 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Arrowhead Pharmaceuticals	Neutral

Gemini Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Gemini Therapeutics' return on equity of -38.78% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Arrowhead Pharmaceuticals has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Arrowhead Pharmaceuticals	$829.45M	11.37	-$1.63M	-$2.25	N/A

Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

Arrowhead Pharmaceuticals has a consensus price target of $99.15, indicating a potential upside of 48.08%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Arrowhead Pharmaceuticals beats Gemini Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Gemini Therapeutics compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Gemini Therapeutics (NASDAQ:GMTX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

Kymera Therapeutics has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market.

Gemini Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Gemini Therapeutics has lower revenue, but higher earnings than Kymera Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	244.87	-$311.35M	-$3.24	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Kymera Therapeutics currently has a consensus price target of $133.21, suggesting a potential upside of 15.36%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kymera Therapeutics is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.88
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

75.4% of Gemini Therapeutics shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Kymera Therapeutics had 6 more articles in the media than Gemini Therapeutics. MarketBeat recorded 6 mentions for Kymera Therapeutics and 0 mentions for Gemini Therapeutics. Kymera Therapeutics' average media sentiment score of 0.75 beat Gemini Therapeutics' score of 0.00 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Kymera Therapeutics	Positive
Gemini Therapeutics	Neutral

Summary

Kymera Therapeutics beats Gemini Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Gemini Therapeutics compare to Abivax?

Abivax (NASDAQ:ABVX) and Gemini Therapeutics (NASDAQ:GMTX) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

47.9% of Abivax shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Abivax currently has a consensus target price of $156.69, suggesting a potential upside of 66.46%. Given Abivax's stronger consensus rating and higher probable upside, equities analysts clearly believe Abivax is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Gemini Therapeutics' return on equity of -38.78% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-91.69%	-71.96%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Abivax has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market.

In the previous week, Abivax had 18 more articles in the media than Gemini Therapeutics. MarketBeat recorded 18 mentions for Abivax and 0 mentions for Gemini Therapeutics. Gemini Therapeutics' average media sentiment score of 0.00 beat Abivax's score of -0.17 indicating that Gemini Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Abivax	Neutral
Gemini Therapeutics	Neutral

Summary

Abivax and Gemini Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Gemini Therapeutics compare to Protagonist Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market.

Protagonist Therapeutics has a net margin of 29.40% compared to Gemini Therapeutics' net margin of 0.00%. Protagonist Therapeutics' return on equity of 12.03% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Protagonist Therapeutics	29.40%	12.03%	11.23%

Gemini Therapeutics has higher earnings, but lower revenue than Protagonist Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Protagonist Therapeutics	$46.02M	195.03	-$130.15M	$1.03	134.66

In the previous week, Protagonist Therapeutics had 1 more articles in the media than Gemini Therapeutics. MarketBeat recorded 1 mentions for Protagonist Therapeutics and 0 mentions for Gemini Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.76 beat Gemini Therapeutics' score of 0.00 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Protagonist Therapeutics	Very Positive

75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Protagonist Therapeutics has a consensus price target of $147.13, suggesting a potential upside of 6.08%. Given Protagonist Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protagonist Therapeutics is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89

Summary

Protagonist Therapeutics beats Gemini Therapeutics on 13 of the 15 factors compared between the two stocks.

Get Gemini Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GMTX vs. The Competition

Export

Metric	Gemini Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.97B	$3.98B	$7.32B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-68.48	13.88	274.01	25.69
Price / Sales	N/A	1,411.37	667.24	93.60
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	23.70	15.30	10.44	6.32
Net Income	-$71.87M	-$22.82M	$3.49B	$359.73M
7 Day Performance	1.75%	-0.22%	0.51%	1.35%
1 Month Performance	-14.20%	-6.06%	-3.38%	-3.68%
1 Year Performance	11.36%	34.37%	16.04%	5.56%

Gemini Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GMTX Gemini Therapeutics	N/A	$68.48 0.0%	N/A	+12.7%	$2.97B	N/A	N/A	30	High Trading Volume
KRYS Krystal Biotech	3.6641 of 5 stars	$336.67 0.0%	$365.40 +8.5%	+112.1%	$9.97B	$389.13M	42.19	295	Positive News Analyst Forecast
ARWR Arrowhead Pharmaceuticals	2.6193 of 5 stars	$65.79 -6.9%	$99.15 +50.7%	+124.2%	$9.95B	$829.45M	N/A	711	High Trading Volume
KYMR Kymera Therapeutics	1.9127 of 5 stars	$116.33 +2.8%	$131.63 +13.1%	+139.3%	$9.41B	$39.21M	N/A	273	Analyst Forecast
ABVX Abivax	2.3746 of 5 stars	$102.23 -4.2%	$156.38 +53.0%	+19.6%	$9.31B	N/A	N/A	69	Trending News Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GMTX) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gemini Therapeutics (GMTX) Competitors

GMTX vs. KRYS, ARWR, KYMR, ABVX, and PTGX

How does Gemini Therapeutics compare to Krystal Biotech?

Summary

How does Gemini Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Gemini Therapeutics compare to Kymera Therapeutics?

Summary

How does Gemini Therapeutics compare to Abivax?

Summary

How does Gemini Therapeutics compare to Protagonist Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMTX vs. The Competition

Gemini Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gemini Therapeutics (GMTX) Competitors

GMTX vs. KRYS, ARWR, KYMR, ABVX, and PTGX

How does Gemini Therapeutics compare to Krystal Biotech?

Which has preferable earnings and valuation, GMTX or KRYS?

Do analysts prefer GMTX or KRYS?

Which has more volatility & risk, GMTX or KRYS?

Do insiders and institutionals have more ownership in GMTX or KRYS?

Does the media favor GMTX or KRYS?

Is GMTX or KRYS more profitable?

Summary

How does Gemini Therapeutics compare to Arrowhead Pharmaceuticals?

Does the media refer more to GMTX or ARWR?

Is GMTX or ARWR more profitable?

Do insiders & institutionals hold more shares of GMTX or ARWR?

Which has stronger valuation & earnings, GMTX or ARWR?

Which has more volatility and risk, GMTX or ARWR?

Do analysts prefer GMTX or ARWR?

Summary

How does Gemini Therapeutics compare to Kymera Therapeutics?

Which has more volatility & risk, KYMR or GMTX?

Is KYMR or GMTX more profitable?

Which has higher valuation and earnings, KYMR or GMTX?

Do analysts prefer KYMR or GMTX?

Do institutionals and insiders have more ownership in KYMR or GMTX?

Does the media refer more to KYMR or GMTX?

Summary

How does Gemini Therapeutics compare to Abivax?

Do institutionals and insiders hold more shares of ABVX or GMTX?

Do analysts prefer ABVX or GMTX?

Which has better earnings and valuation, ABVX or GMTX?

Is ABVX or GMTX more profitable?

Which has more volatility and risk, ABVX or GMTX?

Does the media refer more to ABVX or GMTX?

Summary

How does Gemini Therapeutics compare to Protagonist Therapeutics?

Which has more volatility & risk, GMTX or PTGX?

Is GMTX or PTGX more profitable?

Which has better earnings and valuation, GMTX or PTGX?

Does the media favor GMTX or PTGX?

Do institutionals & insiders have more ownership in GMTX or PTGX?

Do analysts rate GMTX or PTGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMTX vs. The Competition

Gemini Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools